eClinical Technology and Industy News

Aitia and G3 Therapeutics Publish Results Identifying New Causal Biomarkers of Atherosclerotic Coronary Artery Disease (ASCAD), the Leading Cause of Morbidity and Mortality Worldwide

  • Triglyceride-rich LDL particles were found to be directly causal in ASCAD based on Aitia’s Digital Twins built on G3’s Global Multi-omic Clinical Study Data and Aitia’s Causal AI Technology
  • LDL-Triglycerides may become an important diagnostic biomarker in ASCAD and may lead to new therapeutics 

Excerpt from the Press Release:

ATLANTA and SOMERVILLE, Mass., Jan. 12, 2023 /PRNewswire/ — G3 Therapeutics, a life sciences company that leverages large-scale multi-omic biological big data to develop life-changing therapeutics and diagnostics, and Aitia, the leader in the application of Causal AI and “Digital Twins” to discover and develop new drugs, today announced results of research that identified new causes of ASCAD.

The results are found in the paper “Bayesian network analysis of panomic biological big data identifies the importance of triglyceride-rich LDL in atherosclerosis development’, published in the journal Frontiers in Cardiovascular Medicine (

The analysis conducted by G3 Therapeutics, Aitia, and their team of scientific collaborators discovered that triglyceride-rich LDL particles appeared directly upstream from ASCAD in the Digital Twin models, suggesting causality of triglyceride-rich LDL particles. The role of the triglyceride-rich LDL particles was independent of the cholesterol content of LDL particles (independent of LDL-C) and the potential causality was further confirmed by genetic validation, based on the hepatic lipase gene (“LIPC”). The analysis also revealed that atherogenic lipoproteins, inflammation, and endothelial dysfunction are involved in ASCAD, lending additional credence to the novel findings.

These findings imply that LDL-TG could be a novel diagnostic marker for ASCAD and could also open up potential novel treatment targets for atherosclerosis, focusing on triglyceride-rich LDL particles.

Click the button below to read the entire Press Release:

Continue Reading The Press Release

Discover What Sets TrialStat Apart From Ordinary EDC Platforms

Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.

Request Your Demo Today!

From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?